Kiora Pharmaceuticals, Inc. Common Stock (KPRX)
Kiora Pharmaceuticals, Inc. (KPRX) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for ocular diseases. The company aims to address unmet medical needs in eye health, particularly targeting conditions such as uveitis and other inflammatory ocular disorders. Kiora’s pipeline includes novel drug candidates designed to improve treatment outcomes and patient quality of life.
Company News
The article discusses the advancements in gene therapy for Stargardt disease, a genetic eye disorder, and highlights the significant investment and interest in developing long-term treatments. It mentions over 20 companies working on 25+ pipeline drugs to improve the treatment landscape.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
HC Wainwright & Co. has decided to maintain its Buy rating of Kiora Pharmaceuticals (NASDAQ:KPRX) and raise its price target from $3.50 to $2.00. Shares of Kiora Pharmaceuticals are trading down 0.84% over the last 24 hours, at $0.66 per share. A move to $2.00 would account for a 202.57% increase from the current share price. About Kiora Pharmaceuticals Kiora Pharmaceuticals Inc is a clinical-stage specialty pharmaceutical company. It focuses on developing and commercializing products for treating diseases and disorders of the eye. It operates in ...Full story available on Benzinga.com
Penny stocks to watch with news this month. The post 7 Penny Stocks To Watch With Big News In February; Time To Buy? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.